An interventional study of 400 mg CITRAPEAK® (glucosyl-hesperidin) supplementation and Placebo in Exercise Performance, Exercise Recovery and Cognitive Function, sponsored by Lindenwood University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-12.
Sponsored by Lindenwood University · Not applicable, Interventional, and Treatment
The purpose of this study is to evaluate the dose-dependent effects of glucosyl-hesperidin (CITRAPEAK) supplementation on exercise performance, recovery indicators, blood flow, cognitive function, mood, sleep, and fuel utilization in recreationally active adults.
This randomized, double-blind, placebo-controlled study investigates the effects of glucosyl-hesperidin (CITRAPEAK) on exercise performance, recovery, cognitive function, mood, and cardiovascular health in approximately 60 healthy, recreationally active adults aged 18-50. Participants will be assigned to one of three groups (placebo, 200mg CITRAPEAK, or 400mg CITRAPEAK) based on sex and baseline fat-free mass. Each participant will consume their assigned supplement daily for 8 weeks, with adherence tracked via supplementation logs. The study includes multiple visits, where participants will undergo a range of assessments, including exercise performance tests, blood flow analysis, and cognitive evaluations.
Lindenwood University is the lead sponsor of 29 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this arm will receive a placebo supplement consisting of 400 mg of cellulose per day. The placebo is designed to match the appearance and dosage form of the active interventions, allowing for blinding in the study.
Dietary Supplement: Placebo
Participants in this arm will receive a total of 200 mg of glucosyl-hesperidin (CITRAPEAK®) supplementation per day, along with an additional 200 mg of cellulose. This will provide a daily dosage of 400 mg, maintaining blinding to ensure the placebo effect is accounted for.
Dietary Supplement: 200 mg CITRAPEAK® (glucosyl-hesperidin) supplementation
Participants in this arm will receive a total of 400 mg of glucosyl-hesperidin (CITRAPEAK®) supplementation per day. This higher dose is intended to evaluate its effects on exercise performance, recovery, and cognitive function compared to the placebo and lower dose.
Dietary Supplement: 400 mg CITRAPEAK® (glucosyl-hesperidin) supplementation
The active intervention consists of 400 mg of glucosyl-hesperidin (CITRAPEAK®) in capsule form.
The placebo intervention consists of 400 mg/day of cellulose in capsule form, matching the appearance and dosage of active interventions.
The active intervention includes 200 mg of glucosyl-hesperidin (CITRAPEAK®) and an additional 200 mg of cellulose in capsule form.
Change from Baseline in Peak VO2 at Week 8 Following Glucosyl-Hesperidin (CITRAPEAK) Supplementation
Peak VO2 will be measured as an indicator of maximal aerobic capacity. Higher values reflect improved cardiovascular performance.
Time frame: Baseline and Week 8
Change from Baseline in Wingate Anaerobic Test Peak Anaerobic Power at Week 8 Following Glucosyl-Hesperidin (CITRAPEAK) Supplementation
Peak anaerobic power will be measured to assess maximal power output during high-intensity exercise. Higher values indicate improved anaerobic performance.
Time frame: Baseline and Week 8
Change from Baseline in Wingate Anaerobic Test Mean Anaerobic Power at Week 8 Following Glucosyl-Hesperidin (CITRAPEAK) Supplementation
Wingate Anaerobic Test Mean anaerobic power will be recorded during repeated high-intensity exercise, with higher values indicating enhanced anaerobic endurance.
Time frame: Baseline and Week 8
Change from Baseline in Fatigue Rate at Week 8 Following Glucosyl-Hesperidin (CITRAPEAK) Supplementation
Wingate Anaerobic Test Fatigue rate will be measured as the decline in power over time during anaerobic exercise, with a lower rate indicating improved endurance.
Time frame: Baseline and Week 8
Change from Baseline in Perceived Indicators of Recovery, Training Readiness, Soreness, and Overall Feel Using Visual Analog Scales (VAS) at Week 8 Following Glucosyl-Hesperidin (CITRAPEAK) Supplementation
Perceived recovery, training readiness, soreness, recovery, and general "feel" will be self-rated using visual analog scales (VAS), with higher values indicating greater perceived improvements in each category.
Time frame: Baseline and Week 8
Change from Baseline in Brachial Artery Blood Flow Measured 0, 30, and 60 Minutes After Acute and Prolonged Ingestion of Glucosyl-Hesperidin (CITRAPEAK)
Brachial artery blood flow will be measured to assess vascular response to CITRAPEAK at baseline and after 8 weeks of supplementation, with measurements taken at 0, 30, and 60 minutes post-ingestion.
Time frame: Baseline and Week 8, measured at 0, 30, and 60 minutes post-ingestion.
Change from Baseline in Carbohydrate and Fat Oxidation Rates at 30%, 40%, 50%, 60%, 70%, and 80% Peak VO2 During Exercise at Week 8 Following Glucosyl-Hesperidin (CITRAPEAK) Supplementation
Carbohydrate and fat oxidation rates will be measured at incremental intensities to assess fuel utilization during exercise, with higher fat oxidation indicating improved metabolic flexibility.
Time frame: Baseline and Week 8
Change from Baseline in Stroop Color Matching Test Performance 0, 30, and 60 Minutes After Ingesting Dose 1 (Week 0) and Dose 56 (Week 8) Following Glucosyl-Hesperidin (CITRAPEAK) Supplementation
The Stroop color matching test will be conducted to assess cognitive processing speed and accuracy. Testing will occur at 0, 30, and 60 minutes after ingestion of the initial dose (Week 0) and the final dose (Week 8). Improved scores indicate enhanced cognitive performance.
Time frame: 0, 30, and 60 minutes post-ingestion at baseline and Week 8
Change from Baseline in Trail Making Test Performance 0, 30, and 60 Minutes After Ingesting Dose 1 (Week 0) and Dose 56 (Week 8) Following Glucosyl-Hesperidin (CITRAPEAK) Supplementation
The Trail Making Test will be conducted to evaluate cognitive flexibility and executive function. Testing will occur at 0, 30, and 60 minutes after ingestion of the initial dose (Week 0) and the final dose (Week 8). Faster completion times indicate improved cognitive function.
Time frame: 0, 30, and 60 minutes post-ingestion at baseline and Week 8
Change from Baseline in Profile of Mood States (POMS) Score at Week 8 Following Glucosyl-Hesperidin (CITRAPEAK) Supplementation
The Profile of Mood States (POMS) questionnaire will assess mood states across several domains, with lower scores indicating improved mood and well-being.
Time frame: Baseline and Week 8
Change from Baseline in Pittsburgh Sleep Quality Index (PSQI) Score at Week 8 Following Glucosyl-Hesperidin (CITRAPEAK) Supplementation
The Pittsburgh Sleep Quality Index (PSQI) will assess subjective sleep quality, with lower scores reflecting better sleep.
Time frame: Baseline and Week 8
Change from Baseline in Plasma Nitric Oxide Levels at Week 8 Following Glucosyl-Hesperidin (CITRAPEAK) Supplementation
Plasma nitric oxide levels will be measured to evaluate changes in endothelial function, with higher levels suggesting improved vasodilation.
Time frame: Baseline and Week 8
Plan to share: No — We do not plan to share IPD
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lindenwood University